Information for the public
What has NICE said?
Migalastat (Galafold) is recommended. It is a possible treatment for some people with Fabry disease who are over 16 and who would usually be offered enzyme replacement therapy.
Migalastat should be available on the NHS within 3 months.
If you are not eligible for treatment as described above, you should be able to continue taking migalastat until you and your doctor decide it is the right time to stop.
The condition and the treatment
Fabry disease is an inherited disorder caused by an enzyme called alpha-galactosidase A not working properly. This leads to a harmful build-up of a certain type of fat in the body. This causes a range of symptoms, including widespread pain, and sometimes permanent damage to the kidneys and heart.
Migalastat is a drug that binds to alpha-galactosidase A, helping it to work better in some people with Fabry disease.
These organisations can give you advice and support:
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.